Tradr 2X Long SNPS Daily ETF | 10-Q: FY2025 Q3 Revenue: USD 203.37 K

LB filings
2025.11.14 21:29
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 203.37 K.

EPS: As of FY2025 Q3, the actual value is USD -1.56.

EBIT: As of FY2025 Q3, the actual value is USD -1.843 M.

Segment Revenue

  • Revenues from TAO Staking: $203,371 for the three months ended September 30, 2025, and $207,333 for the nine months ended September 30, 2025.

Operational Metrics

  • Net Loss: - $3,923,247 for the three months ended September 30, 2025, compared to - $5,742,013 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $21,054,156 compared to - $7,222,021 in 2024.
  • Operating Expenses: Total operating expenses were $2,002,871 for the three months ended September 30, 2025, compared to $1,978,044 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $6,111,831 compared to $5,250,505 in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: - $3,944,213 for the nine months ended September 30, 2025, compared to - $3,716,123 for the same period in 2024.
  • Net Cash Used in Investing Activities: - $17,570,203 for the nine months ended September 30, 2025, compared to - $1,000,000 in 2024.
  • Net Cash Provided by Financing Activities: $5,303,622 for the nine months ended September 30, 2025, compared to - $4,319,595 used in 2024.

Unique Metrics

  • Digital Assets: As of September 30, 2025, the company held digital assets valued at $15,381,039, with a cost basis of $17,570,103, resulting in an unrealized loss of $2,396,497.

Future Outlook and Strategy

  • Core Business Focus: The company has adopted a cryptocurrency treasury strategy focused on the TAO token, aiming to stake TAO for revenue generation and capital appreciation. Approximately 88% of the company’s treasury holdings were invested in TAO as of September 10, 2025.
  • Non-Core Business: The company is exploring strategic alternatives, including potential drug development platforms and new technologies, as part of its efforts to enhance shareholder value.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.